

Health Discovery Corporation

[View the current Health Discovery Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32441-Health+Discovery+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/32441-Health+Discovery+Corporation.html>)

Contact Details:

5501 1/2 Abercorn St

Savannah

GA

31405

United States of America

Tel: 912.352.7488

Fax: 800.493.7712

Email: info@healthdiscoverycorp.com

Our Mission Leverage Health Discovery's intellectual property and clinical partnerships as the world technology leader in biomarker discovery and the science of pharmacogenomics to develop drugs that promise maximum therapeutic benefits with minimal risks for each individual patient. Our Vision Our vision is to reshape the delivery of medicine in order to redefine the relationship between diagnostics, therapeutics and treatment by delivering personalized medicine that incorporates patient-specific information from gene expression, proteomics, metabolic indicators and therapeutic response. Market Opportunity The Food and Drug Administration (FDA), following its initiative in 1987 to expedite approval for new drugs, is encouraging biomarker discovery as key to early detection diagnostics and avoiding newdrug failures in late stage trials. In July 2004, Health Discovery bought the rights to use a patent portfolio of machine learning tools to identify key biomarkers in diagnostics and drug discovery. In May, the Company acquired complete control over the portfolio, comprising over 70 patents and giving Health Discovery ownership of additional patents that are the basis for initiating licensing arrangements and partnerships with numerous businesses unrelated to drug discovery.

Recent Publications by Health Discovery Corporation:



- [Human growth from the cell to the organism: saltations and integrative physiology.](#)
The Society for the Study of Human Biology has been at the forefront in... 11th November, 2009
Department of Anthropology, Predictive Health Center for Health Discovery,- Ann Hum Biol. 2009 Sep-Oct;36(5):478-95. ([DOI Direct Link](#))
- [Fractal genomics modeling: a new approach to genomic analysis and biomarker discovery.](#)
Reverse engineering of genetics networks generally requires establishing... 18th July, 2006
Health Discovery Corporation, Inc., Savannah, GA 31406, USA.- Proc IEEE Comput Syst Bioinform Conf. 2004:9-18.

- [Optical micturition interval monitor for experimental animals.](#)
*INTRODUCTION: In the past several years, overactive bladder and urinary...*9th July, 2004
Woman's Health Discovery Research, Urologic Disorders, Wyeth- J Pharmacol Toxicol Methods. 2002 Nov-Dec;48(3):147-52. ([DOI Direct Link](#))
- [Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice.](#)
*Atherosclerosis is a chronic inflammatory disease that develops in...*14th January, 2004
Cardiovascular-Women's Health Discovery Research, Wyeth Research,- Am J Transplant. 2003 May;3(5):562-9.
- [Functional annotation of the putative orphan Caenorhabditis elegans G-protein-coupled receptor C10C6.2 as a FLP15 peptide receptor.](#)
*This report describes the cloning and functional annotation of a...*6th January, 2004
Animal Health Discovery Research, Pharmacia Corporation, Kalamazoo, MI- J Biol Chem. 2003 Oct 24;278(43):42115-20. Epub 2003 Aug 22. ([DOI Direct Link](#))
- [Differential activation of "social" and "solitary" variants of the Caenorhabditis elegans G protein-coupled receptor NPR-1 by its cognate ligand AF9.](#)
*Natural variations of wild Caenorhabditis elegans isolates having either...*8th October, 2003
Animal Health Discovery Research, Pharmacia Corp., Kalamazoo, Michigan- J Biol Chem. 2003 Sep 5;278(36):33724-9. Epub 2003 Jun 23. ([DOI Direct Link](#))
- [Marcfortine and paraherquamide class of anthelmintics: discovery of PNU-141962.](#)
*Three distinct chemical classes for the control of gastrointestinal...*9th August, 2003
Animal Health Discovery Research, Kalamazoo, MI 49001, USA.- Curr Top Med Chem. 2002 Jul;2(7):779-93.
- [Restricted conformation analogues of an anthelmintic cyclodepsipeptide.](#)
*Six analogues of the anthelmintic cyclodepsipeptide PF1022A were prepared...*24th June, 2003
Animal Health Discovery Research, Pharmacia Animal Health, Kalamazoo,- J Med Chem. 2003 May 22;46(11):2057-73. ([DOI Direct Link](#))
- [AF2 interaction with Ascaris suum body wall muscle membranes involves G-protein activation.](#)
*KHEYLRF-NH(2) (AF2) is the most abundant FMRFamide-related peptide (FaRP)...*16th April, 2003
Animal Health Discovery Research, PHARMACIA Corporation, Mail stop- Biochem Biophys Res Commun. 2003 Feb 7;301(2):456-9.

Press Releases on Health Discovery Corporation:

River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries	21st November, 2009	American Society of Tropical Medicine and Hygiene	WASHINGTON, Nov. 21 /PRNewswire-USNewswire/ -- A regional initiative launched in the 1990s to eliminate onchocerciasis (river blindness) in the Americas has substantially reduced the prevalence of the
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries	21st November, 2009	The American Society of Tropical Medicine and Hygiene	-- Extending a Hand: Eli Lilly's TB Drug Discovery Partnership -- Gail H. Cassell, Eli Lilly & Co., Indianapolis, IN The aim of the symposium was to illustrate how industry

AARP Hosts Rep. Bill Foster In Health Care Reform Forum	21st November, 2009	AARP Illinois	Association Discusses Key Provisions of Legislation, Continues Push for Progress on Health Care Reform ST. CHARLES, Ill., Nov. 21 /PRNewswire-USNewswire/ -- With the U.S. House of Representatives AUL Action Campaign: Vote NO on Cloture "This bill provides for unprecedented expansion of federally-funded abortion. Real health care respects life, not ends it." Charmaine Yoest
Senate Poised to Advance Majority Leader Reid's Anti-Life Bill	21st November, 2009	Americans United for Life Action	NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI) today announced that it will broadcast Doctor Radio Reports: What Every Women Needs to Know About Mammograms, an in-depth
SIRIUS XM to Broadcast Doctor Radio Reports: What Every Woman Needs to Know About Mammograms	20th November, 2009	SIRIUS XM Radio	

BioNews Results for Health Discovery Corporation



- [SENSA\(R\) WEIGHT-LOSS PROGRAM: The Accidental Discovery That's Transforming The Way People Lose Weight Breaks t](#)
Montana's News Station: Nov 14 2009 5:59PM Matching: health discovery
- [Medical News: Discovery Of Mechanism Of Insulin Production May Lead To Better Treatment For Diabetes](#)
BioFind: Nov 14 2009 12:57PM Matching: health discovery
- [SENSA\(R\) WEIGHT-LOSS PROGRAM: The Accidental Discovery That's Transforming The Way People Lose Weight Breaks t](#)
KSLA: Nov 14 2009 4:23PM Matching: health discovery
- [SENSA\(R\) WEIGHT-LOSS PROGRAM: The Accidental Discovery That's Transforming The Way People Lose Weight Breaks t](#)
KLFY: Nov 14 2009 3:55AM Matching: health discovery
- [Discovery Of Mechanism Of Insulin Production May Lead To Better Treatment For Diabetes](#)
Medical News Today: Nov 14 2009 8:50AM Matching: health discovery
- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Succ](#)
CNW Telbec: Nov 13 2009 3:16PM Matching: health discovery
- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Succes](#)
Canada NewsWire: Nov 13 2009 5:42PM Matching: health discovery
- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery](#)

[Research, AstraZeneca, Named his Successor](#)

Red Orbit: Nov 13 2009 4:19PM Matching: health discovery

- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor](#)

Red Orbit: Nov 13 2009 4:19PM Matching: health discovery

- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor](#)

Red Orbit: Nov 13 2009 4:19PM Matching: health discovery

- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor](#)

Red Orbit: Nov 13 2009 4:18PM Matching: health discovery

- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor](#)

Red Orbit: Nov 13 2009 4:17PM Matching: health discovery

- [Lilly \(Eli\) & Co : Dr Steven Paul Retire from ...](#)

Investigate: Nov 13 2009 2:35PM Matching: health discovery

- [Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor](#)

Earthtimes.org: Nov 13 2009 2:29PM Matching: health discovery

- [SENSA\(R\) WEIGHT-LOSS PROGRAM: The Accidental Discovery That's Transforming The Way People Lose Weight Breaks t](#)

TickerTech.com: Nov 13 2009 8:10PM Matching: health discovery

Health Discovery Corporation Patents:



- 7542959- [Feature selection method using support vector machine classifier](#)
- 6944602- [Spectral kernels for learning machines](#)
- 6996549- [Computer-aided image analysis](#)
- 7117188- [Methods of identifying patterns in biological systems and uses thereof](#)
- 7299213- [Method of using kernel alignment to extract significant features from a large dataset](#)
- 7318051- [Methods for feature selection in a learning machine](#)
- 7353215- [Kernels and methods for selecting kernels for use in learning machines](#)
- 7366719- [Method for the manipulation, storage, modeling, visualization and quantification of datasets](#)
- 7383237- [Computer-aided image analysis](#)
- 7444308- [Data mining platform for bioinformatics and other knowledge discovery](#)
- 7475048- [Pre-processed feature ranking for a support vector machine](#)
- 7542947- [Data mining platform for bioinformatics and other knowledge discovery](#)
- 6920451- [Method for the manipulation, storage, modeling, visualization and quantification of datasets](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

